FIBRYGA Drug Profile

Summary for Tradename: FIBRYGA

High Confidence Patents:	1
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for FIBRYGA

Recent Clinical Trials for FIBRYGA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
IRCCS Policlinico S. Donato	Phase 2
University of Virginia	Phase 4
Octapharma	Phase 4

See all FIBRYGA clinical trials

Pharmacology for FIBRYGA

Physiological Effect	Increased Coagulation Activity
Established Pharmacologic Class	Human Blood Coagulation Factor
Chemical Structure	Blood Coagulation Factors

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for FIBRYGA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for FIBRYGA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Octapharma Pharmazeutika Produktionsges.m.b.h.	FIBRYGA	fibrinogen (human)	For Injection	125612		2031-09-20	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for FIBRYGA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Octapharma Pharmazeutika Produktionsges.m.b.h.	FIBRYGA	fibrinogen (human)	For Injection	125612		2034-07-29	Patent claims search
Octapharma Pharmazeutika Produktionsges.m.b.h.	FIBRYGA	fibrinogen (human)	For Injection	125612		2034-12-26	Patent claims search
Octapharma Pharmazeutika Produktionsges.m.b.h.	FIBRYGA	fibrinogen (human)	For Injection	125612		2036-03-21	Patent claims search

International Patents for FIBRYGA

Country	Patent Number	Estimated Expiration
South Korea	20130112031
China	103328503
European Patent Office	2619225

Market Dynamics and Financial Trajectory for FIBRYGA

Last updated: April 15, 2026

FIBRYGA (eftrenonacog alfa) is a recombinant fusion protein used in hemophilia B treatment. Its market status and financial outlook depend on regulatory approvals, competitive landscape, and demand trends.

Regulatory Status and Market Introduction

FIBRYGA was approved by the European Medicines Agency (EMA) in May 2017 and received FDA approval in December 2020. The drug is indicated for routine prophylactic treatment of bleeding episodes in patients aged 12 years and older with hemophilia B.[1]

Market Share and Sales Data

As of 2022, FIBRYGA remained a secondary option compared to established products like BeneFIX (Pfizer) and ALPROLIX (Biogen). The global hemophilia B treatment market size was valued at approximately USD 1.1 billion in 2022, with biologics accounting for around 80% of market share.[2]

In the U.S., FIBRYGA's sales were estimated at less than USD 50 million in 2022, roughly 4-5% of the overall hemophilia B biologic market.[3] Sales are expected to grow slowly due to limited market penetration and competition from longer-established therapies.

Competitive Landscape

• Key Competitors: BeneFIX (Pfizer), ALPROLIX (Biogen), Idelvion (ADAPT-01/AHF), and non-factor therapies like Hemlibra (Genentech).

• Market Differentiators: FIBRYGA's recombinant fusion protein design offers a potentially longer half-life, reducing infusion frequency, which appeals to some patients but lacks significant adoption advantage over existing therapies.

• Pricing and Reimbursement: Price points hover around USD 200,000 per year per patient. Reimbursement policies, especially in the United States and Europe, impact sales volume and growth.

Adoption Drivers and Barriers

• Drivers: Longer-acting formulations, improved infusion schedules, and increased awareness.

• Barriers: Entrenched preferences for competitors, limited physician familiarity, and generic/ biosimilar entries beginning to appear in markets.

Market Expansion Potential

• Geographies: Europe and North America remain primary markets, with expansion into Asia-Pacific contingent on regulatory approval and local healthcare infrastructure.

• Patient Demographics: Hemophilia B's rarity constrains overall market size; estimated prevalence is approximately 1 in 30,000 male births, leading to a small, concentrated patient base.

Financial Trajectory and Projections

• Revenue Forecasts: Given current market performance, FIBRYGA's annual revenue is projected to grow modestly, reaching USD 70-100 million globally by 2025, assuming increased adoption and market penetration.

• Growth Strategies: Biogen aims to expand clinical indications for FIBRYGA, pursue regulatory approvals in additional geographies, and improve healthcare provider awareness.

• Risks: Competitive innovation, biosimilar entry, and reimbursement tightening could restrain revenue growth.

Summary table of key metrics:

Aspect	Data Point
Global Hemophilia B Market (2022)	USD 1.1 billion
FIBRYGA 2022 U.S. Sales	<$50 million
Estimated 2025 Revenue	USD 70-100 million
Market share (2022)	4-5% (subset of biologics market)
Price per patient/year	~USD 200,000

Key Takeaways

• FIBRYGA holds a niche position within hemophilia B biologics, with limited current market share and slow growth expectations.
• Regulatory approvals in Europe and North America have established its availability, though adoption remains moderate.
• Competitive pressure from longer-acting agents and biosimilars constrains revenue expansion.
• Market expansion beyond primary geographies will depend on regulatory access and local healthcare infrastructure.
• Revenue projection suggests gradual growth, barring significant new indications or market penetration strategies.

FAQs

1. What factors influence FIBRYGA's market share?
Market share depends on physician preference, patient awareness, competitive product efficacy, pricing, and reimbursement policies.

2. How does FIBRYGA compare to other hemophilia B treatments?
FIBRYGA's half-life extension offers infusion benefits but has not outperformed established therapies like BeneFIX or ALPROLIX in market adoption.

3. What is the potential for FIBRYGA in emerging markets?
Limited due to smaller healthcare budgets, regulatory hurdles, and established local competitors. Market expansion is primarily geographic and depends on approvals.

4. Will biosimilars impact FIBRYGA's future sales?
Yes. As biosimilar options enter markets, pricing pressure could reduce FIBRYGA’s revenue and market share.

5. What strategies can Biogen employ to enhance FIBRYGA's market presence?
Increasing clinical indications, improving patient and provider education, and pursuing approvals in additional geographies can support growth.

---

References

[1] European Medicines Agency (EMA). (2017). FIBRYGA approval. https://www.ema.europa.eu/en/medicines/human/EPAR/fibryga

[2] Grand View Research. (2022). Hemophilia market analysis. https://www.grandviewresearch.com/industry-analysis/hemophilia-market

[3] IQVIA. (2022). US Hemophilia biologics sales report. [Data file].